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Abstract
Background: With advances in theinterventional field, the choice between coronary artery 
bypass grafting (CABG) and percutaneous coronary intervention with drug-eluting stents 
(PCI-DES) for the diabetic subset with left main (LM) and/or multivessel disease (MVD) 
remains consistently controversial.
Methods and results: We conducted a systematic review of randomized controlled trials 
(RCTs) and observational controlled trials (OCTs) comparing the two strategies for the diabetic 
subset with LM and/or MVD. PubMed, EMBASE, CENTRAL databases, Google Scholar 
and SinoMed were systematically searched for eligible studies without language and publica-
tion restrictions. We identified 19 trials (4 randomized and 15 nonrandomized), enrolling 
5,805 patients in OCTs and 3,060 patients in RCTs, respectively. PCI-DES was associated 
with higher mortality compared with CABG (11.7% DES vs. 9.1% CABG, RR 1.23, 95% CI 
1.00–1.53, p = 0.06). Patients after PCI-DES had higher prevalence of myocardial infarction 
(MI) when compared with CABG (8.5% DES vs. 4.6% CABG, RR 1.68, 95% CI 1.20–2.37, 
p = 0.003). PCI-DES patients were at substantially lower risk of stroke (2.0% DES vs. 3.9% 
CABG, RR 0.51, 95% CI 0.39–0.67, p < 0.00001), but at several-fold higher risk of repeat 
revascularization (19.0% DES vs. 6.3% CABG, RR 2.95, 95% CI 2.46–3.55, p < 0.00001). 
The OCT patients risked a lower mortality as compared to the RCT patients (9.6% OCTs vs. 
11.9% RCTs, RR 0.81, 95% CI 0.71–0.92, p = 0.001).
Conclusions: CABG for patients with diabetes mellitus and LM and/or MVD had advan-
tages over PCI-DES in all-cause death, nonfatal MI, and repeat revascularization, but the 
substantial disadvantage in nonfatal stroke. The high-selected patients (RCTs) risked a higher 
mortality than the real-world patients (OCTs). (Cardiol J 2015; 22, 2: 123–134)
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Introduction
Diabetes mellitus is a powerful, independent 
risk factor for cardiovascular disease and accounts 
for about 25% of all patients requiring myocardial 
revascularization [1, 2]. Patients with diabetes have 
more extensive and diffuse coronary artery disease 
(CAD) than nondiabetic patients [3, 4], and have 
higher mortality and morbidity after revascular-
ization procedures, including myocardial infarction 
(MI), restenosis after balloon angioplasty [4–7], 
and bare-metal stenting [8]. Despite significant 
improvements in the CAD mortalities in the past 
decades, due to atherosclerosis resulting in MI, 
CAD remains the leading death death worldwide 
[5]. Coronary artery bypass grafting (CABG) was 
generally regarded as a preferred revascularization 
strategy for patients with left main (LM) and/or 
multivessel disease (MVD) [9]. However, the ad-
vances in the interventional field, especially the 
advent and development of drug-eluting stents 
(DES), which significantly reduced restenosis and 
the need for subsequent repeat revascularizations 
as compared with bare metal stents (BMS), have 
largely cut back one of the major limitations of per-
cutaneous coronary interventions (PCI) [10–18]. 
Several randomized controlled trials (RCTs), exclu-
sively comparing CABG surgery and PCI with DES 
(PCI-DES) for the diabetic subset with LM and/or 
MVD [19–22], have reported medium- and long- 
-term outcomes, but given high-selected patients in 
the RCTs, their applicability to the general popula-
tion is unknown. The observational controlled trial 
(OCTs), unlike the RCTs, can reflect daily clinical 
practice in the real world. We conducted a system-
atic review and meta-analysis of randomized and 
nonrandomized studies to establish clinical efficacy 
and safety of PCI-DES vs. CABG in patients with 
diabetes and LM and/or MVD both in the real world 
(OCTs) and in high-selected population (RCTs).
Methods
Search strategy
We systematically searched PubMed, EM-
BASE, the Cochrane Central Register of Con-
trolled Trials, Google Scholar and SinoMed for 
relevant studies reported from January 2002 (the 
year when the DESs were introduced to clinical 
practice) to December 2013, without language and 
publication restrictions. To achieve the maximum 
sensitivity of the search strategies and identify all 
trials comparing PCI-DES with CABG in diabetic 
subset, we appropriately used both free text and 
thesaurus terms, including: ‘multivessel disease’, 
‘left main’, ‘diabetes mellitus’, ‘percutaneous 
coronary intervention’, ‘drug-eluting stents’, and 
‘coronary artery bypass’. We also performed 
a systematic search from reference lists of selected 
articles, conference proceedings, and personal files 
for relevant citations.
Inclusion and exclusion criteria
Studies were included in this meta-analysis if 
they met the following criteria: 1) RCT, OCT and 
pre-specified subgroup analyses comparing CABG 
with PCI-DES for diabetics with LM and/or MVD; 
2) studies published in peer-reviewed journals 
with full available text; and 3) follow-up period 
≥ 12 months. Studies were excluded if they met any 
of the following criteria: 1) the subjects were not 
exclusively diabetics with LM and/or MVD, 2) us-
ing only BMS or involving BMS with DES in 1 PCI 
subject, 3) duplicate publication, 4) less than 
50 patients in each cohort.
Study selection
Two reviewers screened the citations and ab-
stracts identified by the search strategies. Full text 
reviews were also conducted by 2 other reviewers 
to establish eligibility when screening reviewers 
believed that a citation potentially met the inclu-
sion criteria. Disagreements regarding inclusion 
were resolved via consensus.
Data extraction
Three reviewers independently extracted data 
from the eligible studies. The following informa-
tion were extracted from each study: first author, 
year of publication, duration of follow-up, number 
of participants in each group (CABG or PCI-DES), 
baseline characteristics, and outcome events in-
cluding: all-cause mortality (the primary outcome), 
non-fatal MI, non-fatal stroke and repeat revascu-
larization (Table 1). Each OCT was named by the 
family name plus the publication year (family name 
+ year) respectively, and the RCT was presented 
as its own study name. For studies reported in 
> 1 publications, we extracted data from the most 
complete publication and used other publications 
as supplements. We also tried our best to contact 
the authors by email for information if their articles 
did not report the information in detail.
Statistical methods
Data were summarized using descriptive 
statistics. Discrete variables were presented as 
proportions (%, count/sample size) and compared 
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by the c2 test or Fisher’s exact test, where appro-
priate. Continuous variables were presented as 
mean ± standard deviation and compared using 
the Student’s t-test. The verified data were ana-
lyzed using Revman software (version 5.2). The 
endpoints of each study were analyzed using risk 
ratio (RR) with 95% confidence interval (CI). The 
Cochrane c2 (Cochrane Q) test was used to assess 
Table 1. Baseline characteristics of clinical studies.
Study or subgroup Location or  
centers (n)
Subjects (n)
(DES/CABG)
Design Follow-up Type of revas-
cularization
Coronary  
lesion
Ben-Gal, 2006 [23] Israel 86/86 OCT 18 months DES/CABG Single,  
multivessel  
and/or  
LM disease
Briguori, 2007 [24] Italy 69/149 OCT 1 year DES/OPCABG MVD and critical 
stenosis involv-
ing proximal LAD
Contini, 2012 [25] Italy 359/359 OCT 5 years DES/CABG MVD
Domínguez-Franco, 
2008 [26]
Spain 128/142 OCT 24 months DES/CABG MVD  
(≥ 2 vessels  
with a > 70%  
de novo stenosis 
involving the 
proximal LAD)
Javaid, 2007 [27] United States 344/257‡, OCT 12 months DES/CABG MVD
Kim, 2009 [28] 12 251/256 OCT 3 years SES, PES/ 
/CABG
Unprotected  
LMCAD  
(defined as  
stenosis ≥ 50%)
Lee, 2007 [29] United States 102/103 OCT 1 year DES/CABG MVD
Luo, 2012 [30] China 99/127 OCT 25.3 months DES/CABG Unprotected  
LMCAD  
(defined as  
stenosis ≥ 50%)
Moshkovitz, 2012 [31] Israel 271/226 OCT 62 months DES/BITA MVD
Onuma, 2011 [32] Netherlands 159 /96 OCT 5 years SES/CABG MVD
Park, 2011 [33, 34] Korea 489/402 OCT§ 5.6 years DES/CABG MVD
Qiao, 2009 [35] China 363/282 OCT 12 months DES/CABG MVD 
Tarantini, 2009 [36] Italy 93/127 OCT 2 years DES/CABG MVD
Yamagata, 2010 [37] Japan 92/116 OCT 42 months SES/OPCAB MVD
Zhao, 2011 [38] China 56/116 OCT 28.5 months 
DES;  
28.4 months 
CABG
DES/CABG LMCAD
CARDia [22] 24 256/254 RCT 5.1 years BMS, DES/ 
/CABG*
MVD or complex 
single-vessel 
CAD
FREEDOM [21] 140 953/947 RCT 3.8 years SES, PES/ 
/CABG
MVD
SYNTAX [20] 85 231/221 RCT§ 5 years PES/CABG LM (isolated or in 
addition to  
1-, 2-, or 3-vessel 
disease) or  
isolated 3-vessel 
disease
VA CARDS [19] 22 101/97 RCT 2 years DES/CABG Severe CAD
OCT — observational controlled trial; RCT — randomized controlled trial; CABG — coronary artery bypass grafting; OPCABG — off-pump 
CABG; DES — drug-eluting stents; SES — sirolimus-eluting stent; PES — paclitaxel-eluting stents; LAD — left anterior descending artery; 
BITA — bilateral internal mammary artery; LM — left main disease; MVD — multivessel disease; CAD — coronary artery disease;  
‡combining 2-vessel subgroups and 3-vessel subgroups; §pre-specified subgroup-analysis; *bare metal stents 31%, drug eluting stents 69%
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the between-trial heterogeneity. The I2 statistic 
was calculated as a measure of the proportion of 
the overall variation attributable to the between-
trial heterogeneity rather than to chance, and we 
used the reported guidelines for low (I2 = 25–49%), 
moderate (I2 = 50–74%), and high (I2 ≥ 75%) 
heterogeneity [39]. The overall effect size (RR) 
was calculated by fixed-effect model with the 
Mantel-Haenszel method when there was no 
significant heterogeneity (p > 0.10 or I2 < 50%), 
or with DerSimonian-Laird weights for the ran-
dom-effects model when there was a significant 
heterogeneity (p ≤ 0.10 or I2 ≥ 50%). Forest plots 
were then created for graphical presentations of 
clinical outcomes. Publication bias with respect 
to the primary outcome (all-cause death) was as-
sessed visually using a funnel plot. When there is 
no publication bias, studies of all sizes are scat-
tered equally right and left of the line indicating 
the pooled estimate of natural log RR. For each 
endpoint we conducted subgroup analyses in RCTs 
and OCTs respectively, apart from an overall analy-
sis. A sensitivity analysis was performed when the 
between-trial heterogeneity was significant.
Results
We identified 19 eligible studies (4 randomized 
[19–22] and 15 nonrandomized [23–38]) (Fig. 1) en-
rolling 5,805 patients in OCT subgroup (PCI-DES: 
2,961; CABG: 2,844) and 3,060 in RCT subgroup 
(PCI-DES: 1,541; CABG: 1,519), respectively. The 
mean follow-up durations ranged from 1 year to 
5.6 years. In the OCTs, with the exception of the pro-
pensity score-matched studies [23, 25], the CABG 
cohorts had higher prevalence of the triple vessel 
and/or LM disease, higher EuroSCORE and/or high-
er SYNTAX Score, but not in the RCTs (Table 2). 
Figure 1. Flow diagram for inclusion of studies; OCTs — observational controlled trials; RCTs — randomized 
controlled trials.
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The CARDia trial included patients initially un-
dergoing PCI with BMS (BMS 31%, DES 69%) 
[22]. The VA CARDS trial was stopped because of 
slow recruitment after enrolling only 25% of the 
intended sample size, leaving it severely under-
powered for the primary composite endpoint of 
death plus nonfatal MI [19].
All-cause death
Random-effects meta-analysis yielded two differ-
ent outcomes for all-cause death in RCTs and OCTs 
subgroup. The prevalence of death in RCTs subgroup 
was 14.0% in the PCI-DES cohort and 9.6% in CABG 
cohort with an RR of 1.51 (95% CI 1.09–2.10, p = 0.01). 
A moderate heterogeneity among the RCTs, mainly 
driven by including the VA CARDS trial, was revealed 
by sensitivity analysis (I2 = 52%, p = 0.10). After ex-
cluding VA CARDS trial, random-effects model gener-
ated an RR 1.36, 95% CI 1.11–1.66 for death (p = 0.003) 
with no residual heterogeneity (I2 = 0%, p = 0.53). 
While the OCT subgroup analysis indicated a compa-
rable mortality between PCI-DES and CABG (10.3% 
DES vs. 8.8% CABG, RR 1.08, 95% CI 0.83–1.42, 
p = 0.55), heterogeneity analysis revealed a low het-
erogeneity among the OCTs (I² = 45%, p = 0.03) 
which was largely due to the inclusion of the Javaid, 
2007 trial. After the exclusion of this trial, random-
-effects meta-analysis yielded an RR 1.02 (95% CI 
0.85–1.22) for death (p = 0.80) with no residual 
heterogeneity (I² = 0%, p = 0.73).
When pooling all the RCTs and OCTs, random-
-effects model yielded an RR 1.23 (11.7% DES vs. 
9.1% CABG, 95% CI 1.00–1.53, p = 0.06) for death. 
After excluding the VA CARDS trial and the Javaid, 
2007 trial, the overall mortalities of the two arms 
reached statistical difference (RR 1.15, 95% CI 
1.01–1.31, p = 0.04) with no residual heterogeneity 
between trials (I2 = 0%, p = 0.51) (Fig. 2, Table 3). 
There was an asymmetry of the points on visual 
estimation of the funnel plot, which indicated the 
possibility of publication bias with respect to the 
primary outcome (all-cause death) (Fig. 3).
Nonfatal myocardial infarction
The RCT subgroup analysis demonstrated no 
difference in MI incidence (10.3% DES vs. 5.9% 
CABG, RR 1.44, 95% CI 0.79–2.60, p = 0.23), 
with a significant between-trial heterogeneity 
Figure 2. All-cause mortality at longest follow-up. The individual trials and subtotal risk ratios and 95% confidence 
intervals (CI) comparing the outcome of death for percutaneous coronary intervention with drug-eluting stents 
(PCI-DES) vs. coronary artery bypass grafting (CABG).
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Table 3. Sensitivity analysis.
Outcome  
(total subjects)
PCI-DES  
(%)
CABG  
(%)
RR 95%  
[CI]
P Heterogeneity
OCT analysis after  
excluding:  
Javaid, 2007 trial
Death  
(n = 4,691)
231/2,341 
(9.9%)
223/2,350 
(9.5%)
1.02  
[0.86–1.22]
0.80 I² = 0% 
P = 0.73
RCT analysis after  
excluding:  
VA CARDS trial
Death  
(n = 2,854) 
Myocardial  
infarction  
(n = 2,854) 
Repeat  
revascularization  
(n = 2,854)
195/1,438 
(13.56%) 
153/1,438 
(10.64%) 
 
249/1,438 
(17.32%)
141/1,416 
(9.96%) 
75/1,416 
(5.30%) 
 
93/1,416 
(6.57%)
1.36  
[1.11–1.66] 
2.01  
[1.54–2.62] 
 
2.61  
[2.09–3.27]
0.003 
 
< 0.00001 
 
 
< 0.00001
I² = 0% 
P = 0.53 
I² = 0% 
P = 0.83 
 
I² = 0% 
P = 0.89
Overall analysis  
after excluding:  
VA CARDS trial
Death  
(n = 7,545)# 
Myocardial  
infarction  
(n = 7,467) 
Repeat  
revascularization  
(n = 8,643)
426/3,779 
(11.27%) 
326/3,786 
(8.61%) 
 
834/4,394 
(18.98%)
364/3,766 
(9.67%) 
159/3,681 
(4.32%) 
 
255/4,249 
(6.00%)
1.15  
[1.01–1.31] 
1.91  
[1.43–2.57] 
 
2.99  
[2.62–3.42]
0.04 
 
< 0.0001 
 
 
< 0.00001
I² = 0% 
P = 0.51 
I² = 43% 
P = 0.04 
 
I² = 0% 
P = 0.57
#Excluding VA CARDS trial and Javaid, 2007 trial; RCTs — randomized controlled trials; OCTs — observational controlled trial; RR — risk ratio; 
CI — confidence interval; PCI-DES — percutaneous coronary intervention with drug-eluting stents; CABG — coronary artery bypass grafting
Figure 3. Funnel plot for assessment of publication bias 
of trials for the endpoint of all-cause death; OCTs — 
observational controlled trial; RCTs — randomized con-
trolled trials. 
(I² = 75%, p = 0.007). Sensitivity analysis showed 
that this heterogeneity was largely contributed by 
the inclusion of the VA CARDS trial, where MI 
rate after CABG was much higher than that after 
PCI-DES, unlike other RCTs. When excluding this 
trial, random-effects meta-analysis demonstrated 
a statistical difference (10.6% DES vs. 5.3% CABG, 
RR 2.01, 95% CI 1.54–2.62, p < 0.00001) with no re-
sidual heterogeneity (I² = 0%, p = 0.83). The OCT 
subgroup analysis showed that MI after PCI-DES 
was more prevalent as opposed to CABG (7.4% 
DES vs. 3.7% CABG, RR 1.82, 95% CI 1.15–2.86, 
p = 0.01) with a moderate heterogeneity (I² = 54%, 
p = 0.01), for which no special trial was mostly 
responsible.
Regardless of the inclusion or exclusion 
of the VA CARDS trial, random-effects meta-
analysis showed that the overall MI rate was con-
sistently higher in PCI-DES patients (inclusion: 
8.5% DES vs. 4.6% CABG, RR 1.68, 95% CI 1.20–
–2.37, p = 0.003; exclusion: 8.6% DES vs. 4.3% 
CABG, RR 1.91, 95% CI 1.43–2.57, p < 0.0001) 
(Fig. 4, Table 3).
Nonfatal stroke
Fixed-effects meta-analysis revealed that both 
in the RCTs and OCTs subgroup PCI-DES was as-
sociated with much lower risk of stroke compared 
with CABG (RCTs: 2.3% DES vs. 3.8% CABG, 
RR 0.59, 95% CI 0.39–0.90, p = 0.01; OCTs: 1.8% 
DES vs. 4.0% CABG, RR 0.46, 95% CI 0.32–0.66, 
p < 0.0001) with no heterogeneity between trials 
(RCTs: I2 = 0%, p = 0.94; OCTs: I2 = 0%, p = 0.57). 
When pooling two subgroups, PCI-DES patients 
kept a consistently lower frequency of stroke (2.0% 
DES vs. 3.9% CABG, RR 0.51, 95% CI 0.39–0.67, 
p < 0.00001) with no heterogeneity between trials 
(I2 = 0%, p = 0.80) (Fig. 5).
Repeat revascularization
The RCT subgroup analysis showed that 
patients after PCI-DES risk a several-fold higher 
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Figure 4. Nonfatal myocardial infarction at longest follow-up. The individual trials and subtotal risk ratios and 95% 
confidence intervals (CI) comparing the outcome of myocardial infarction for percutaneous coronary intervention with 
drug-eluting stents (PCI-DES) vs. coronary artery bypass grafting (CABG).
Figure 5. Nonfatal stroke at longest follow-up. The individual trials and subtotal risk ratios and 95% confidence inter-
vals (CI) comparing the outcome of stroke for percutaneous coronary intervention with drug-eluting stents (PCI-DES) 
vs. coronary artery bypass grafting (CABG).
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rate of subsequent revascularization (17.4% DES 
vs. 7.4% CABG, RR 2.11, 95% CI 1.41–3.15, 
p = 0.0003), even if including the VA CARDS trial 
which primarily contributed to the significant hetero- 
geneity among RCTs (I2 = 71%, p = 0.01). After 
exclusion of this trial, the point estimate for repeat 
revascularization reached a statistical significance 
(17.32% DES vs. 6.57% CABG, RR 2.61, 95% CI 
2.09–3.27, p < 0.00001) with no residual hetero-
geneity (I2 = 0%, p = 0.89). The OCT subgroup 
analysis suggested patients after PCI-DES was at 
a substantially higher risk of repeat revasculariza-
tion (19.8% DES vs. 5.7% CABG, RR 3.22, 95% 
CI 2.73–3.80, p = 0.0001) with no heterogeneity 
among OCTs (I2 = 0%, p = 0.53).
Random-effects meta-analysis showed that the 
overall incidence of subsequent revascularization 
was consistently much higher in PCI-DES cohort 
regardless of the inclusion or exclusion of the 
VA CARDS trial (inclusion: 19.0% DES vs. 6.3% 
CABG, RR 2.95, 95% CI 2.46–3.55, p < 0.00001; 
exclusion: 19.0% DES vs. 6.0% CABG, RR 2.99, 
95% CI 2.62–3.42, p < 0.0001) (Fig. 6, Table 3).
Discussion
To the best of our knowledge, this study, in-
corporating more than 8,000 patients, is the first 
systematic review and meta-analysis of both the 
randomized and nonrandomized studies that com-
pared PCI-DES vs. CABG in diabetic subset with 
LM and/or MVD. Not only did this meta-analysis 
conclude the overall efficacy and safety of the 
two revascularization strategies in the general 
population, but also compared the two strategies 
in real-world patients (OCTs) and in high-selected 
patients (RCTs), respectively.
It is well known that the RCTs are the most 
convincing in all types of studies, while the OCTs, 
unlike the RCTs which enroll the high-selected 
subjects, can reflect daily clinical practice where 
the choice between two revascularization strate-
gies mostly depends on the clinician’s discretion 
and the patient’s will. Actually, compared with 
nondiabetic patients, diabetics risk higher mortality 
after either DES or CABG, which demonstrated 
that neither CABG nor PCI could eliminate the 
Figure 6. Repeat revascularization at longest follow-up. The individual trials and subtotal risk ratios and 95% confi-
dence intervals (CI) comparing the outcome of repeat revascularization for percutaneous coronary intervention with 
drug-eluting stents (PCI-DES) vs. coronary artery bypass grafting (CABG).
www.cardiologyjournal.org 131
Fumei Huang et al., PCI-DES vs. CABG in diabetic patients with LM and/or MVD
increased mortality risk conferred by diabetes mel-
litus [40]. However, CABG was generally considered 
a preferred revascularization strategy for patients 
with LM and/or MVD [9]. In the daily practice, the 
clinicians preferred CABG for the patients with 
more complex lesions regardless of diabetes mel-
litus status, whereas patients who have local dis-
eases and less extensive lesions were more likely to 
undergo DES. Thus, in the OCTs, the CABG cohorts 
had higher-risk profiles for clinical and angiographic 
characteristics, which were revealed by the higher 
EuroSCORE and/or higher SYNTAX score, and by 
the higher prevalence of triple and/or left main CAD 
in the CABG cohort (Table 2).
Several previous meta-analyses comparing 
PCI-DES vs. CABG for diabetics showed that no 
significant differences in death and MI were found, 
but the lower risk of repeat revascularization and 
the higher risk of stroke in CABG patients had 
been definitely revealed [41, 42]. The FREEDOM 
trial was the biggest prospective RCT comparing 
the two revascularization modalities for diabetic 
patients with MVD exclusively. The significantly 
higher mortality and MI but the lower rate of stroke 
in the PCI-DES group was observed actually at 
its 5-year follow-up, even though this trial was 
underpowered to detect a difference in all-cause 
mortality [21]. However, the debate had not been 
discontinued. Subsequently, the SYNTAX trial 
compared CABG with PCI using paclitaxel-eluting 
stents (PCI-PES) for patients with LM and/or 
three-vessel disease, and its subgroup analysis for 
the diabetic subset revealed that the mortalities 
of two strategies were not statistically different 
(19.5% DES vs. 12.9% CABG, p = 0.065), but 
this analysis was also underpowered and limited 
by being post hoc exploratory subgroup analysis 
[20, 43]. The Hakeem et al. trial [44], the first 
meta-analysis of RCTs on this topic, revealed that 
CABG improved survival, decreased MI and repeat 
revascularization, but increased the risk of stroke 
compared with multivessel PCI with first-gener-
ation DES. Generally, it was definite that patients 
after CABG patients risked more strokes and less 
repeat revascularization compared with PCI-DES 
patients. Through the sensitivity analyses and 
the subgroup analyses (the same results from two 
subgroup analyses), this meta-analysis further 
confirmed that CABG had significant advantage in 
repeat revascularization but the substantial disad-
vantage in stroke.
The funnel plot showed that the studies were 
mainly scattered left of the line, which revealed that 
publication bias possibly existed and the advantage 
of CABG in all-cause death was likely underesti-
mated (Fig. 3). However, the RCT subgroup analysis 
and the overall sensitivity analysis demonstrated 
that CABG had an advantage over PCI-DES with 
the respects of all-cause death. The RCT subgroup 
analysis showed that CABG improved survival com-
pared with PCI-DES, while the OCT subgroup analy-
sis demonstrated the comparable mortality between 
two strategies (Fig. 2, Table 3). The different out-
comes between the OCT and RCT subgroup analysis 
were likely to be driven by the higher-risk profiles 
for clinical and angiographic characteristics in CABG 
cohort in the OCTs, while the RCTs had compa-
rable risk factor between two cohorts (Table 2), 
which was possibly another reason for the asym-
metry of the funnel plot. The comparable survival 
between two strategies in OCT subgroup and the 
lower mortality of the OCT patients than RCT pa-
tients (9.6% OCTs vs. 11.9% RCTs, RR 0.81, 95% CI 
0.71–0.92, p = 0.001) suggested that the preferred 
choice of CABG for diabetic patients with higher-
risk profiles in daily clinical practice was reasonable 
in terms of all-cause death. Conclusively, CABG had 
advantage over PCI-DES with respect of the primary 
endpoint despite the different results between RCTs 
and OCTs subgroup analyses.
Only the VA CARDS trial conducted the ag-
gressive search for silent MI, while other RCTs 
included silent MI when discovered but not man-
dated serial electrocardiography and nuclear stud-
ies, which was one of the reasons that the MI rate 
following CABG was much higher than that after 
PCI-DES [19], which pronouncedly differed from 
other RCTs. However, regardless of inclusion or 
exclusion of the VA CARDS trial, our study con-
firmed consistently that PCI-DES was associated 
with higher MI rate compared with CABG. The 
CABG advantage over PCI-DES in MI was also 
revealed by the Lee et al. [42] trial which was 
a meta-analysis including OCTs only and by the 
Hakeem et al. trial [44] which was a meta-analysis 
including RCTs only. Generally, the advantage of 
CABG in MI was definite, but it was unknown 
whether this advantage was kept when silent MI 
was aggressively searched for.
Limitations of the study
We acknowledged that our study had sev-
eral limitations. Firstly, the observational studies 
enrolled in this mate-analysis had their inherent 
limitations, namely design bias, selection bias, 
treatment bias and publication bias. Substantial 
between-studies heterogeneity in terms of both 
study design and the effect sizes of each end point 
132 www.cardiologyjournal.org
Cardiology Journal 2015, Vol. 22, No. 2
were observed in this review. Furthermore, this 
meta-analysis contained trials regardless of the 
baseline characteristics of patients, medication 
treatment after revascularization, duration of fol-
low-up and location of occlusion, which might bring 
about more heterogeneity. Thus, despite our choice 
of random effects models, the incorporating of 
disparate studies could not accurately summarize 
the overall effect of two strategies, and also limits 
the generalizability of our results. Secondly, the 
first-generation DES, used mostly in the included 
studies, could not fully reflect the clinical practice 
in the newer-generation DES era. Recent data from 
a Swedish registry, enrolling 4,751 diabetic patients, 
showed that the use of the second-generation 
stents (everolimus-eluting stent) was associated 
with improved outcomes compared with the first-
generation (PES and sirolimus-eluting stents), but 
the result was mainly driven by lower rates of stent 
thrombosis and death [45]. Whether CABG keeps 
the priority to the PCI-DES is unknown. Thirdly, 
several trials reporting the in-hospital and 30-day 
follow-up result showed that CABG was associated 
with increased major adverse cardiac events, death, 
stroke. The meta-analysis for these short-term 
endpoints was not conducted by our study, which 
makes it difficult to evaluate the efficacy and safety 
of the two strategies entirely.
Conclusions
CABG for patients with diabetes mellitus and 
LM and/or MVD had advantages over PCI-DES in 
all-cause death, nonfatal MI, and repeat revasculari-
zation, but one substantial disadvantage in nonfatal 
stroke. The high-selected patients (RCTs) risked 
a higher mortality than the real-world patients (OCTs).
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